GCM
TEVA icon

Graham Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Graham Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35,457
Closed -$545K – 1619
2025
Q1 		$545K Sell
35,457
-40,775
-53% -$728K 0.01% 768
2024
Q4 		$1.68M Buy
76,232
+45,542
+148% +$829K 0.03% 348
2024
Q3 		$553K Sell
30,690
-6,241
-17% -$109K 0.01% 613
2024
Q2 		$600K Sell
36,931
-108,899
-75% -$1.68M 0.01% 530
2024
Q1 		$2.06M Buy
145,830
+7,562
+5% +$95.3K 0.04% 248
2023
Q4 		$1.44M Buy
+138,268
New +$1.29M 0.03% 284
2015
Q1 		– Sell
-60,000
Closed -$3.45M – 152
2014
Q4 		$3.45M Buy
60,000
+25,000
+71% +$1.39M 0.15% 88
2014
Q3 		$1.88M Buy
35,000
+30,800
+733% +$1.63M 0.08% 109
2014
Q2 		$220K Hold
4,200
– – 0.01% 151
2014
Q1 		$222K Buy
+4,200
New +$194K 0.01% 103

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Graham Capital Management's TEVA Position: Q2 2025 in Review

Graham Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2025, closing a stake of 35,457 shares — an estimated $545K sold.

Graham Capital Management first reported a position in TEVA in Q1 2014 and held it in 10 quarters. The position peaked at $3.45M in Q4 2014. 539 funds tracked by Wall St. Rank hold TEVA as of Q2 2025.

  • Graham Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Graham Capital Management sold 35,457 Teva Pharmaceuticals shares in Q2 2025, an estimated $545K.
  • Graham Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 10 quarters.
  • Graham Capital Management's Teva Pharmaceuticals position peaked at $3.45M in Q4 2014.
  • 539 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2025.

Based on Graham Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.